Press Releases Items Per Page 102550 News Category FinancialGeneral Year None202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology Nov 10, 2019 Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 09, 2019 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019 Nov 06, 2019 Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting Nov 01, 2019 Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets Oct 30, 2019 Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma Oct 16, 2019 Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis Oct 07, 2019 Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting Oct 02, 2019 Nektar Announces Key Executive Promotions Oct 01, 2019 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Sep 26, 2019 Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »